Cancer Biomarkers: Can We Turn Recent Failures into Success?

被引：259

作者：

Diamandis, Eleftherios P. ^{[1
,2
]}

机构：

[1] Univ Toronto, Mt Sinai Hosp, Dept Clin Biochem, Univ Hlth Network,Dept Clin Biochem, Toronto, ON M5T 3L9, Canada

[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5T 3L9, Canada

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2010年 / 102卷 / 19期

关键词：

MAGNETIC-RESONANCE SPECTROSCOPY; OVARIAN-CANCER; PROSTATE-CANCER; PROTEOMIC PATTERNS; LYSOPHOSPHATIDIC ACID; MALIGNANT-TUMORS; SERUM; MARKERS; PLASMA; EPCA-2;

D O I：

10.1093/jnci/djq306

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Disease biomarkers are used widely in medicine. But very few biomarkers are useful for cancer diagnosis and monitoring. Over the past 15 years, major investments have been made to discover and validate cancer biomarkers. Despite such investments, no new major cancer biomarkers have been approved for clinical use for at least 25 years. In the last decade, many reports have described new cancer biomarkers that promised to revolutionize the diagnosis of cancer and the management of cancer patients. However, many initially promising biomarkers have not been validated for clinical use. In this commentary, a plethora of parameters before sample analysis, during sample analysis, and after sample analysis that can complicate biomarker discovery and validation and lead to "false discovery" are discussed. Several examples of biomarker discoveries that were published in high-profile journals are also presented, as well as why they were not validated and the lessons learned from these false discoveries, so that similar mistakes can be avoided in the future.

引用

页码：1462 / 1467

页数：6

共 39 条

[31] Opinion - Bias as a threat to the validity of cancer molecular-marker research [J].

Ransohoff, DF .

NATURE REVIEWS CANCER, 2005, 5 (02) :142-149

[32] NMR - ANOTHER CANCER-TEST DISAPPOINTMENT [J].

SHULMAN, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (14) :1002-1003

[33] National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers [J].

Sturgeon, Catharine M. ;

Duffy, Michael J. ;

Hofmann, Barry R. ;

Lamerz, Rolf ;

Fritsche, Herbert A. ;

Gaarenstroom, Katja ;

Bonfrer, Johannes ;

Ecke, Thorsten H. ;

Grossman, H. Barton ;

Hayes, Peter ;

Hoffmann, Ralf-Thorsten ;

Lerner, Seth P. ;

Loehe, Florian ;

Louhimo, Johanna ;

Sawczuk, Ihor ;

Taketa, Kazuhisa ;

Diamandis, Eleftherios P. .

CLINICAL CHEMISTRY, 2010, 56 (06) :E1-E48

[34] National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers [J].

Sturgeon, Catharine M. ;

Duffy, Michael J. ;

Stenman, Ulf-Hakan ;

Lilja, Hans ;

Brunner, Nils ;

Chan, Daniel W. ;

Babaian, Richard ;

Bast, Robert C., Jr. ;

Dowell, Barry ;

Esteva, Francisco J. ;

Haglund, Caj ;

Harbeck, Nadia ;

Hayes, Daniel F. ;

Holten-Andersen, Mads ;

Klee, George G. ;

Lamerz, Rolf ;

Looijenga, Leendert H. ;

Molina, Rafael ;

Nielsen, Hans Jorgen ;

Rittenhouse, Harry ;

Semjonow, Axel ;

Shih, Ie-Ming ;

Sibley, Paul ;

Soletormos, Gyorgy ;

Stephan, Carsten ;

Sokoll, Lori ;

Hoffman, Barry R. ;

Diamandis, Eleftherios P. .

CLINICAL CHEMISTRY, 2008, 54 (12) :E11-E79

[35] National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements [J].

Sturgeon, Catharine M. ;

Hoffman, Barry R. ;

Chan, Daniel W. ;

Ch'ng, Soo-Ling ;

Hammond, Elizabeth ;

Hayes, Daniel F. ;

Liotta, Lance A. ;

Petricoin, Emmanuel F. ;

Schmitt, Manfred ;

Semmes, O. John ;

Soletormos, Gyorg ;

van der Merwe, Elena ;

Diamandis, Eleftherios P. .

CLINICAL CHEMISTRY, 2008, 54 (08) :E1-E10

[36] Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer [J].

Timms, John F. ;

Cramer, Rainer ;

Camuzeaux, Stephane ;

Tiss, Ali ;

Smith, Celia ;

Burford, Brian ;

Nouretdinov, Ilia ;

Devetyarov, Dmitry ;

Gentry-Maharaj, Aleksandra ;

Ford, Jeremy ;

Luo, Zhiyuan ;

Gammerman, Alex ;

Menon, Usha ;

Jacobs, Ian .

CLINICAL CHEMISTRY, 2010, 56 (02) :262-271

[37] Differential exoprotease activities confer tumor-specific serum peptidome patterns [J].

Villanueva, J ;

Shaffer, DR ;

Philip, J ;

Chaparro, CA ;

Erdjument-Bromage, H ;

Olshen, AB ;

Fleisher, M ;

Lilja, H ;

Brogi, E ;

Boyd, J ;

Sanchez-Carbayo, M ;

Holland, EC ;

Cordon-Cardo, C ;

Scher, HI ;

Tempst, P .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :271-284

[38] Diagnostic markers for early detection of ovarian cancer [J].

Visintin, Irene ;

Feng, Ziding ;

Longton, Gary ;

Ward, David C. ;

Alvero, Ayesha B. ;

Lai, Yinglei ;

Tenthorey, Jeannette ;

Leiser, Aliza ;

Flores-Saaib, Ruben ;

Yu, Herbert ;

Azori, Masoud ;

Rutherford, Thomas ;

Schwartz, Peter E. ;

Mor, Gil .

CLINICAL CANCER RESEARCH, 2008, 14 (04) :1065-1072

[39] Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers [J].

Xu, Y ;

Shen, ZZ ;

Wiper, DW ;

Wu, MZ ;

Morton, RE ;

Elson, P ;

Kennedy, AW ;

Belinson, J ;

Markman, M ;

Casey, G .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (08) :719-723

← 1 2 3 4 →